km.idaeo.ai · IDAEO 知識庫

🏛 本文属于主题馆「reports」 →

颞下颌关节与颌面全指南：TMD 分类地图、保守优先的处置阶梯、急性脱位路径，以及正颌与颌面手术的科别界线｜證據鏈

km 編輯部2026-08-13阅读约 123 分钟
#證據鏈#牙醫領域#顎關節#矯正

本頁是〈颞下颌关节与颌面全指南：TMD 分类地图、保守优先的处置阶梯、急性脱位路径，以及正颌与颌面手术的科别界线〉的事實單元帳：每一條主張對應的來源、證據等級、地域與期間、原文引句與限制，逐條攤開。

颞下颌关节与颌面全指南：TMD 分类地图、保守优先的处置阶梯、急性脱位路径，以及正颌与颌面手术的科别界线｜證據鏈

F-Units 事实帐

  • F1｜来源#3｜confidence: high｜basis: textbook｜geo: universal｜period: 2020-03-12｜claim: 颞下颌关节紊乱病是一组超过 30 种、与颞下颌关节以及颌部肌肉与组织相关的健康疾患。｜span: "are a set of more than 30 health disorders associated with both the temporomandibular joints and the muscles and tissues of the jaw"｜caveat: 出自国家科学院共识研究报告之书目描述，属领域范围界定而非治疗建议；本站保守以 textbook 级收录，不upgrade 为 clinical_guideline。
  • F2｜来源#3｜confidence: medium｜basis: textbook｜geo: universal｜period: 2020-03-12｜claim: 颞下颌关节紊乱病成因多样，且常与头痛、纤维肌痛、背痛与肠易激综合征等多种重叠的医疗状况并存。｜span: "TMDs have a range of causes and often co-occur with a number of overlapping medical conditions, including headaches, fibromyalgia, back pain and irritable bowel syndrome"｜caveat: 为报告的描述性陈述，未提供各共病的发生率；不得据此推导因果方向。
  • F3｜来源#2｜confidence: high｜basis: clinical_guideline｜geo: universal｜period: 2023-12-15｜claim: 颞下颌关节紊乱病是仅次于下背痛的第二常见肌肉骨骼慢性疼痛疾患，影响全球 6% 至 9% 的成人。｜span: "TMD are the second most common musculoskeletal chronic pain disorder after low back pain, affecting 6-9% of adults globally"｜caveat: 出自指南之现况背景段；此数字统计的是慢性疼痛人群，与以 DC/TMD 诊断之患病率（F4）口径不同，禁互相取代或合并。
  • F4｜来源#4｜confidence: high｜basis: peer_reviewed（PMID 33409693，系统综述与荟萃分析）｜geo: universal｜period: 2021-02｜claim: 颞下颌关节疾患的整体患病率合并估计为成人与老年人群约 31.1%、儿童与青少年约 11.3%；关节盘移位分别为 19.1% 与 8.3%，退行性关节病分别为 9.8% 与 0.4%。｜span: "The main results from prevalence overall meta-analyses for adults/elderly are as follows: TMJD (31.1%), DDs (19.1%), and DJD (9.8%). Furthermore, for children/adolescents are as follows: TMJD (11.3%), DDs (8.3%), and DJD (0.4%)."｜caveat: 为人群层级之合并估计，非个人风险；纳入研究之风险偏倚分布见 F7。
  • F5｜来源#4｜confidence: high｜basis: peer_reviewed（PMID 33409693）｜geo: universal｜period: 2021-02｜claim: 患病率居前的个别颞下颌关节疾患诊断为可复性关节盘移位，成人与老年人群约 25.9%、儿童与青少年约 7.4%。｜span: "Considering the individual diagnosis meta-analyses, the most prevalent TMJD is DDwR for adults/elderly (25.9%) and children/adolescents (7.4%)."｜caveat: 「患病率居前」为原文 most prevalent 之对译；不代表该诊断需要治疗。
  • F6｜来源#4｜confidence: high｜basis: peer_reviewed（PMID 33409693）｜geo: universal｜period: 2021-02｜claim: 该综述所调查的颞下颌关节疾患类别包含关节痛、可复性关节盘移位、伴间歇性绞锁的可复性关节盘移位、伴开口受限的不可复性关节盘移位、不伴开口受限的不可复性关节盘移位、退行性关节病、骨关节炎、骨关节病与半脱位。｜span: "The TMJD investigated were as follows: arthralgia, disk displacement (DDs) with reduction (DDwR), DDwR with intermittent locking, DDs without reduction (DDwoR) with limited opening, DDwoR without limited opening, degenerative joint disease (DJD), osteoarthritis, osteoarthrosis, and subluxation."｜caveat: 此为该综述调查的诊断类别列举，非完整的 DC/TMD 分类系统；完整分类见来源#1。
  • F7｜来源#4｜confidence: high｜basis: peer_reviewed（PMID 33409693）｜geo: universal｜period: 2021-02｜claim: 该综述自 2741 篇文献纳入 21 篇，其中 10 篇评为低偏倚风险、7 篇中等、4 篇高；纳入条件限以 RDC/TMD 或 DC/TMD 诊断之观察性研究。｜span: "From 2741 articles, 21 were included. Ten studies were judged at low RoB, seven at moderate, and four at high."｜caveat: 纳入研究之偏倚风险分布不一，合并估计须连同此分布一起读。
  • F8｜来源#1｜confidence: high｜basis: clinical_guideline（PMID 24482784，PubMed 文献类型标示 Practice Guideline）｜geo: universal｜period: 2014-Winter｜claim: DC/TMD 由两次国际共识工作坊产出，其 Axis I 为生理层面诊断算法、Axis II 为心理社会与行为层面之自填评估工具。｜span: "two international consensus workshops were convened, from which recommendations were obtained for the finalization of new Axis I diagnostic algorithms and new Axis II instruments"｜caveat: 本站仅取回 PubMed 摘要全文，标准正文未取回，不作正文逐字引用。
  • F9｜来源#1｜confidence: high｜basis: clinical_guideline（PMID 24482784）｜geo: universal｜period: 2014-Winter｜claim: 验证计划判定旧版 RDC/TMD 的 Axis I 效度低于目标值（目标为敏感度 ≥ 0.70、特异度 ≥ 0.95），此为修订之起因。｜span: "the Validation Project determined that the RDC/TMD Axis I validity was below the target sensitivity of ≥ 0.70 and specificity of ≥ 0.95"｜caveat: 指的是旧版 RDC/TMD，非现行 DC/TMD 之效度。
  • F10｜来源#1｜confidence: high｜basis: clinical_guideline（PMID 24482784）｜geo: universal｜period: 2014-Winter｜claim: 新版 DC/TMD Axis I 对患病率居前之疼痛型 TMD 达敏感度 ≥ 0.86、特异度 ≥ 0.98；对其中一种关节内疾患为敏感度 0.80、特异度 0.97。｜span: "valid diagnostic criteria for differentiating the most common pain-related TMD (sensitivity ≥ 0.86, specificity ≥ 0.98) and for one intra-articular disorder (sensitivity of 0.80 and specificity of 0.97)"｜caveat: 效度数据限于该验证资料集；「一种关节内疾患」不等于全部关节内疾患。
  • F11｜来源#1｜confidence: high｜basis: clinical_guideline（PMID 24482784）｜geo: universal｜period: 2014-Winter｜claim: 其他常见关节内疾患的诊断标准缺乏足够效度以作临床诊断，仅能用于筛查用途。｜span: "Diagnostic criteria for other common intra-articular disorders lack adequate validity for clinical diagnoses but can be used for screening purposes."｜caveat: 本文据此推出的是「可能需要进一步检查或转诊」的方向，未指定任何影像术式或时机。
  • F12｜来源#1｜confidence: high｜basis: clinical_guideline（PMID 24482784）｜geo: universal｜period: 2014-Winter｜claim: Axis II 筛查工具共 41 题，评估疼痛强度、疼痛相关失能、心理困扰、下颌功能限制与异常功能行为；完整版共 81 题，另评估焦虑与共病疼痛状况。｜span: "The screening instruments' 41 questions assess pain intensity, pain-related disability, psychological distress, jaw functional limitations, and parafunctional behaviors"｜caveat: 81 题之完整版内容见同一摘要后句；本文未引用各题目内容。
  • F13｜来源#2｜confidence: high｜basis: clinical_guideline（PMID 38101929，GRADE 方法）｜geo: universal｜period: 2023-12-15｜claim: 该指南对慢性 TMD 疼痛给出强建议支持的介入包含认知行为疗法（可联合生物反馈或放松治疗）、治疗师协助的关节松动术、手法激痛点治疗、监督下姿势运动、监督下颌部运动与拉伸，以及常规照护（居家运动、拉伸、安抚与卫教）；条件性支持者包含手法操作、联合松动之监督下颌部运动、认知行为疗法联合非甾体抗炎药、联合姿势运动之手法操作与针灸。｜span: "strong recommendations in favour of cognitive behavioural therapy (CBT) with or without biofeedback or relaxation therapy, therapist-assisted mobilisation, manual trigger point therapy, supervised postural exercise, supervised jaw exercise and stretching with or without manual trigger point therapy, and usual care (such as home exercises, stretching, reassurance, and education)"｜caveat: 比较基准为安慰剂或假处置；属指南层级建议方向，非对任何个人之处置指示。
  • F14｜来源#2｜confidence: high｜basis: clinical_guideline（PMID 38101929）｜geo: universal｜period: 2023-12-15｜claim: 该指南对可逆式咬合板（单独或联合）、关节腔灌洗、透明质酸注射、低能量激光、经皮神经电刺激、肉毒毒素注射、糖皮质激素注射与数类口服药物，给出条件性不支持之建议。｜span: "conditional recommendations against reversible occlusal splints (alone or in combination with other interventions), arthrocentesis (alone or in combination with other interventions), cartilage supplement with or without hyaluronic acid injection, low level laser therapy (alone or in combination with other interventions), transcutaneous electrical nerve stimulation, gabapentin, botulinum toxin injection, hyaluronic acid injection, relaxation therapy, trigger point injection, acetaminophen (with or without muscle relaxants or NSAIDS), topical capsaicin, biofeedback, corticosteroid injection (with or without NSAIDS), benzodiazepines, and β blockers"｜caveat: 「条件性不支持」为 GRADE 用语，非禁止；药品名称仅出现于本 span 之原文，本文正文不对任何药品作疗效陈述或使用建议。
  • F15｜来源#2｜confidence: high｜basis: clinical_guideline（PMID 38101929）｜geo: universal｜period: 2023-12-15｜claim: 该指南对不可逆式口内咬合装置、关节盘切除术，以及非甾体抗炎药联合阿片类药物，给出强建议不做。｜span: "strong recommendations against irreversible oral splints, discectomy, and NSAIDS with opioids"｜caveat: 适用对象为慢性 TMD 疼痛；不得外推至其他适应证下之同名处置。
  • F16｜来源#2｜confidence: high｜basis: clinical_guideline（PMID 38101929）｜geo: universal｜period: 2023-12-15｜claim: 该指南适用对象限于持续 3 个月以上之慢性 TMD 相关疼痛，不适用于急性 TMD 疼痛；使用方式为先考虑强建议支持者、次为条件性支持者、再次为条件性不支持者，且共同决策为必要。｜span: "These recommendations apply to patients living with chronic pain (≥3 months duration) associated with TMD as a group of conditions, and do not apply to the management of acute TMD pain. When considering management options, clinicians and patients should first consider strongly recommended interventions, then those conditionally recommended in favour, then conditionally against. In doing so, shared decision making is essential to ensure patients make choices that reflect their values and preference, availability of interventions, and what they may have already tried."｜caveat: 本条为指南之适用边界宣告与使用顺序说明（原文 UNDERSTANDING THE RECOMMENDATION 段），是本文区分「慢性路径」与「急性事件」、以及阶梯使用顺序的依据。
  • F17｜来源#2｜confidence: high｜basis: clinical_guideline（PMID 38101929）｜geo: universal｜period: 2023-12-15｜claim: 该指南指出现行临床实践指南多以共识为基础，且提供彼此不一致的建议。｜span: "Current clinical practice guidelines are largely consensus-based and provide inconsistent recommendations."｜caveat: 为该指南之现况评述；本文引用其作为「不同来源结论看起来冲突」的背景说明。
  • F18｜来源#5｜confidence: medium｜basis: peer_reviewed（PMID 41058307，伞状综述）｜geo: universal｜period: 2026-01｜claim: 该伞状综述自 1740 篇文献筛选，纳入 11 篇系统综述、涵盖 49 篇独特原始研究；其中 6 篇报告自我管理之有利结果、5 篇认为证据不足以支持或反对；原始研究重叠率为 53%，主要证据缺口在生活质量与不良反应。｜span: "11 SRs comprising 49 unique primary studies were included. Of these, six SRs reported favorable results for self-management for TMD, whereas five reported insufficient evidence either for or against the use of self-management compared to other interventions. The overlap of primary studies between the SRs was 53%, and the main evidence gaps were related to quality of life and adverse effects outcomes."｜caveat: 为综述之综述，证据强度受原始系统综述质量限制；作者指出纳入 SR 之方法学缺陷。
  • span: "A total of 1740 studies were identified."
  • F19｜来源#5｜confidence: medium｜basis: peer_reviewed（PMID 41058307）｜geo: universal｜period: 2026-01｜claim: 现有证据大致显示，患者卫教、行为治疗与颌部运动等自我管理策略具有有益效果。｜span: "Existing evidence generally suggests beneficial effects from self-management strategies such as patient education, behavioural therapy and jaw exercises."｜caveat: 原文为 generally suggests，属方向性陈述；不得改写为疗效承诺或数值化承诺。
  • F20｜来源#6｜confidence: medium｜basis: peer_reviewed（PMID 39953753，系统综述与荟萃分析）｜geo: universal｜period: 2025-06｜claim: 该荟萃分析自 619 篇研究纳入 6 篇；在开口度上，咬合板组与肉毒毒素组之间未呈现统计学显著差异。｜span: "Out of 619 studies, only six were included in the meta-analysis. The effect size was 0.293 in favour of BTX in the studies evaluating the maximum mouth-opening (MMO) range. However, the amount of MMO did not show a statistically significant difference between the OS and BTX groups (95% CI - 0.383 to 0.969, P = 0.395, z = -0.850)."｜caveat: 仅 6 篇纳入；「无统计学显著差异」为原文逐字（P = 0.395），非本站推估；效应量 0.293 偏向 BTX 但未达显著，不得单引效应量。
  • F21｜来源#6｜confidence: medium｜basis: peer_reviewed（PMID 39953753）｜geo: universal｜period: 2025-06｜claim: 亚组分析显示肉毒毒素组于 1 周时开口度较高、咬合板组于 3 个月时较高，而在 1、2、6 与 12 个月随访点均无显著差异；慢性疼痛分级量表在两组间亦无显著差异。｜span: "it was found that the MMO was statistically significantly higher in the BTX group at the first week and in the OS group at the third month. However, there was no significant difference observed at the first, second, sixth and twelfth month follow-ups (P > 0.05). No significant difference was found between the groups (P > 0.05) in the publications that evaluated the graded chronic pain scale (GCPS)"｜caveat: 本研究比较之对象为两种介入彼此，非与安慰剂比较；不得用以推翻或取代 F14 之指南建议（比较基准不同）。
  • F22｜来源#7｜confidence: medium｜basis: peer_reviewed（PMID 21676208，系统综述）｜geo: universal｜period: 2011-06-15｜claim: 该综述检视 128 篇文献、其中 79 篇判定相关；汇总之病例为急性脱位 79 例、慢性延迟性脱位 35 例、慢性复发性脱位 311 例。｜span: "A total of 128 articles were reviewed out which 79 were found relevant. Of these, 26 were case reports, 17 were case series and 36 were original articles. 79 cases were acute dislocations, 35 cases were chronic protracted TMJ dislocations and 311 cases were chronic recurrent TMJ dislocations."｜caveat: 纳入文献以病例报告与病例系列为主（26 篇病例报告、17 篇病例系列、36 篇原著），非随机对照试验，证据等级偏低。
  • F23｜来源#7｜confidence: medium｜basis: peer_reviewed（PMID 21676208）｜geo: universal｜period: 2011-06-15｜claim: 该综述记录之病因以外伤为主（约 60%），其余约 40% 为其他原因；全部回顾病例中仅 4 例为单侧脱位。｜span: "Etiology was predominantly trauma in 60% of cases and other causes contributed about 40%. Of all the cases reviewed, only 4 were unilateral dislocation."｜caveat: 为文献汇总之比例，受发表偏倚影响，不代表社区人群之病因分布；同一引用池内之来源#8（见 F54）对病因给出不同分布（外伤 4 例、大幅张口 6 例、不明 1 例），两者须并读，不得互相取代或合并。
  • F24｜来源#7｜confidence: high（对结论措辞本身）｜basis: peer_reviewed（PMID 21676208）｜geo: universal｜period: 2011-06-15｜claim: 该综述结论为：更复杂且更具侵入性的治疗方法未必提供较好的选项与治疗结果，因此应先充分用尽并适当运用保守做法，再采用更具侵入性的手术技术。｜span: "The more complex and invasive method of treatment may not necessarily offer the best option and outcome of treatment, therefore conservative approaches should be exhausted and utilized appropriately before adopting the more invasive surgical techniques."｜caveat: 为作者结论之实务原则，未指定任何具体术式的先后顺序或适应证门槛。
  • F25｜来源#8｜confidence: low｜basis: peer_reviewed（PMID 29556163，11 例病例回顾）｜geo: universal｜period: 2017-12｜claim: 在该 11 例病例回顾中，4 例急性病例以 Hippocrates 手法成功复位，1 例于全身麻醉下施行该手法，2 例为自发性复位（原文 spontaneous reduction，指未经手法而复位，非患者自行操作）；复发性病例以该手法联合颌间固定处理。｜span: "4 of the acute cases were successfully managed using the Hippocrates manoeuvre, 1 had the manoeuvre under GA, and 2 had spontaneous reduction. All recurrent cases were successfully managed with the Hippocrates manoeuvre and IMF."｜caveat: 单中心、11 例病例回顾，证据等级低，不可作为发生比例或成功率之推估依据；本文引用其作为「复位属临床处置、部分需全身麻醉」的实证，不作任何操作说明；「自发性复位」为 spontaneous reduction 之对译，指未经手法而复位，禁改写为「患者自行复位」以免与本文的禁令句冲突。
  • span: "Case review of 11 patients with TMJ dislocation seen in the University College Hospital (UCH) Ibadan over a period of 10 years."
  • F26｜来源#8｜confidence: low｜basis: peer_reviewed（PMID 29556163）｜geo: universal｜period: 2017-12｜claim: 该综述结论为：保守的 Hippocrates 复位手法在多数病例有效，且不受脱位持续时间长短影响。｜span: "A conservative method of management - the Hippocrates manoeuvre - was effective in most cases irrespective of duration of dislocation."｜caveat: 样本仅 11 例、随访多在 2 周内，作者亦记录随访配合度不佳；「多数病例有效」不得改写为成功率数字或效果承诺；同一摘要另记载慢性病例仅 5 成以该手法成功处理（见 F55），与本结论句「不受持续时间影响」之方向不一致，引用本条时须与 F55 并读。
  • F27｜来源#9｜confidence: low｜basis: peer_reviewed（PMID 41227277，系统综述，PROSPERO CRD420251139493）｜geo: universal｜period: 2025-11-06｜claim: 针对儿童复发性颞下颌关节脱位，该综述纳入 9 篇研究（1 篇病例对照、3 篇病例系列、5 篇病例报告）；微创与保守方法为较常被描述者，微创中以肉毒毒素注射被报告次数居前。｜span: "nine studies were included: one case-control study, three case series, and five case reports. Invasive treatment methods applied in pediatric patients were reported in two of those. Minimally invasive and conservative treatment methods were most frequently described, with botulinum toxin injections being the most commonly reported minimally invasive approach."｜caveat: 「较常被描述」指的是文献中出现的频率，不等于疗效较佳；药品名称仅出现于本 span 之原文，本文不对其作任何疗效或使用建议。
  • F28｜来源#9｜confidence: high（对「无法得出结论」此结论本身）｜basis: peer_reviewed（PMID 41227277）｜geo: universal｜period: 2025-11-06｜claim: 该综述明言，因异质性与可得文献数量有限，对儿童复发性颞下颌关节脱位各治疗方法之有效性无法得出一致结论。｜span: "Due to the heterogeneity and limited number of available literature, consistent conclusions regarding the effectiveness of different treatment methods for recurrent TMJ dislocation in children could not be drawn."｜caveat: 本条为证据缺口声明；不得由 F27 之「被描述频率」推导疗效排序。
  • F29｜来源#10｜confidence: medium｜basis: peer_reviewed（PMID 36098813，系统综述，PROSPERO CRD42020199591）｜geo: universal｜period: 2022-11｜claim: 该综述针对临界型骨性三类错颌畸形，自 2089 篇文献纳入 6 篇，整体偏倚风险评为中等；因纳入研究间差异相当大，未能进行荟萃分析。｜span: "Out of 2089 retrieved articles, 6 were eligible and thus included in the subsequent analyses. Their overall risk of bias was moderate."｜caveat: 仅 6 篇纳入且无荟萃分析；作者指出部分重要数据缺漏，呼吁进行方法更标准化的研究。
  • F30｜来源#10｜confidence: medium｜basis: peer_reviewed（PMID 36098813）｜geo: universal｜period: 2022-11｜claim: 正畸联合正颌手术对上颌基底有前移效果、对下颌基底有后移效果，因而改善前后向关系，并伴随下颌平面之顺时针旋转；单纯正畸掩饰治疗则对上颌切牙有较大唇倾、对下颌切牙有舌倾效果。｜span: "The OSS has a protrusive effect on the maxillary base, retrusive effect on the mandibular base, and thus improvement in the sagittal relationship accompanied with a clockwise rotational effect on the mandibular plane. The OC has more proclination effect on the maxillary incisors and retroclination effect on the mandibular incisors compared to OOS."｜caveat: 适用对象限「临界型」骨性三类病例，不可外推至所有地包天病例；为方向性效果描述，未提供个人可预期之数值。
  • F31｜来源#11｜confidence: medium｜basis: peer_reviewed（PMID 42273603，系统综述）｜geo: universal｜period: 2026-05-26｜claim: 该综述纳入 65 篇研究、共 6,482 位患者；骨性三类矫正之 ANB 角平均改善 6.8°（95% CI 6.2 至 7.4°），且 87.3% 于一年以上随访维持骨性稳定。｜span: "Sixty-five studies encompassing 6,482 patients were included. Mean ANB angle improvements were 6.8° (95% CI: 6.2-7.4°) for class III and 5.4° (95% CI: 4.9-5.9°) for class II corrections, with 87.3% maintaining skeletal stability at ≥1-year follow-up."｜caveat: 为多篇研究汇总之平均值，非个人可预期之结果；本文仅引用骨性三类之数值。
  • F32｜来源#11｜confidence: medium｜basis: peer_reviewed（PMID 42273603）｜geo: universal｜period: 2026-05-26｜claim: 正颌手术整体并发症率为 32.4%（95% CI 28.7 至 36.1%），以轻微且自限性者为主。｜span: "Overall complication rate was 32.4% (95% CI: 28.7-36.1%), predominantly minor and self-limiting."｜caveat: 人群层级之汇总比例，非个人风险；「以轻微且自限性者为主」为原文描述，未提供严重并发症之细分比例；本数字为该综述 65 篇研究、6,482 位颌面骨性畸形患者之合并值，原文未依骨性分类（class II／III）或术式（BSSO／Le Fort）分层，禁读为任一骨性分类之专属风险。
  • F33｜来源#11｜confidence: medium｜basis: peer_reviewed（PMID 42273603）｜geo: universal｜period: 2026-05-26｜claim: 感觉神经异常发生于 52.8% 的病例，其中 92.6% 于 12 个月内恢复，3.4% 为原文所称 permanent 之未恢复持续性改变。｜span: "Neurosensory disturbances occurred in 52.8% of cases, with 92.6% recovering by 12 months and permanent alterations in 3.4%."｜caveat: 未分术式与部位；本文以「未恢复的持续性感觉改变」对译 permanent，原文用语保留于 span 供查核；同为 6,482 位患者之合并值，原文未依骨性分类分层，禁读为地包天（骨性三类）手术之专属比例。
  • F34｜来源#11｜confidence: medium｜basis: peer_reviewed（PMID 42273603）｜geo: universal｜period: 2026-05-26｜claim: 复发（超过 2 毫米）发生于 18.7% 的病例；生活质量有显著改善（OQLQ 总分标准化平均差 -1.84，95% CI -2.12 至 -1.56）；患者满意度达 87.6%（95% CI 84.2 至 91.0%），美观面评分高于功能面。｜span: "Relapse (>2mm) occurred in 18.7% of cases. Quality of life demonstrated substantial improvements with standardized mean difference of -1.84 (95% CI: -2.12 to -1.56, p < 0.001) for OQLQ total scores. Patient satisfaction reached 87.6% (95% CI: 84.2-91.0%), with higher ratings for aesthetic vs. functional outcomes."｜caveat: 满意度为患者自陈指标，非临床疗效指标；不得作为疗效或结果承诺；复发、生活质量与满意度三项同为 6,482 位患者之合并值，原文未依骨性分类或术式分层。
  • F35｜来源#11｜confidence: high（对结论措辞本身）｜basis: peer_reviewed（PMID 42273603）｜geo: universal｜period: 2026-05-26｜claim: 该综述结论为：中等程度的并发症率与复发风险，使谨慎的患者选择、知情同意与长期随访成为必要。｜span: "However, moderate complication rates and relapse risk necessitate careful patient selection, informed consent, and long-term follow-up."｜caveat: 本条为本文「知情同意与长期随访」段落之单一依据，属国际文献之临床原则陈述，不引用任何国家之法定要件。
  • F36｜来源#12｜confidence: medium｜basis: peer_reviewed（PMID 40360332，系统综述与荟萃分析）｜geo: universal｜period: 2026-01｜claim: 该研究纳入 33 篇研究、其中 29 篇进入荟萃分析；整体而言，上颌与下颌之前后向稳定度在传统三阶段法与手术优先法之间无统计学显著差异（上颌 P = 0.77、下颌 P = 0.072）。｜span: "Thirty-three studies were identified, 29 were included in the meta-analyses. Overall anteroposterior stability of the maxilla and mandible did not differ significantly between CTM and SFA groups (maxilla, P = 0.77; mandible, P = 0.072)."｜caveat: 检索期间为 2010 至 2022 年；「无显著差异」不等于等效。
  • F37｜来源#12｜confidence: low｜basis: peer_reviewed（PMID 40360332）｜geo: universal｜period: 2026-01｜claim: 在二维 X 线影像的分析中，下颌前后向稳定度之结果倾向支持传统三阶段法（P = 0.051），而下颌垂直向稳定度则以手术优先法较佳（P = 0.051）；作者结论为传统三阶段法支持较佳之前后向稳定度。｜span: "In two-dimensional radiographs, the results for anteroposterior stability of the mandible were in favour of CTM (P = 0.051); conversely, vertical stability of the mandible showed better results with SFA (P = 0.051). ... In conclusion, CTM supports better anteroposterior stability."｜caveat: 两项 P 值均为 0.051，未达常用之 0.05 显著水准，且与 F36 之整体结果方向需并读；作者结论之证据强度受 F39 限制。
  • F38｜来源#12｜confidence: medium｜basis: peer_reviewed（PMID 40360332）｜geo: universal｜period: 2026-01｜claim: 手术优先法之疗程时间显著较短（P < 0.001），且于 6 个月随访点的生活质量分数（22 题正颌生活质量问卷）较佳（P = 0.042）。｜span: "SFA patients showed a significantly shorter treatment time (P < 0.001) and better quality of life (22-item Orthognathic Quality of Life Questionnaire) at 6 months follow-up (P = 0.042)."｜caveat: 生活质量差异仅测于 6 个月随访点，未报告更长期之差异。
  • F39｜来源#12｜confidence: high（对限制声明本身）｜basis: peer_reviewed（PMID 40360332）｜geo: universal｜period: 2026-01｜claim: 该研究 33 篇纳入文献中仅 6 篇为随机对照试验，作者明言证据薄弱、结果须谨慎解读。｜span: "However, only six of the 33 included studies were randomized controlled trials, hence in view of the weakness of the evidence, the results should be interpreted with caution."｜caveat: 本条为证据强度上限声明，F36 至 F38 之解读均受其限制。
  • F40｜来源#13｜confidence: medium｜basis: peer_reviewed（PMID 38858245，范围文献综述与队列研究）｜geo: universal｜period: 2024-09｜claim: 该综述自 67 篇文献筛出 22 篇纳入分析，归纳额部处置之重点依序为眉骨突出削减、额鼻角拓宽、眼眶轮廓修整、提眉与发际线前移。｜span: "Initial review yielded sixty-seven articles. Title and abstract review followed by standardized application of inclusion and exclusion criteria resulted in a total of twenty-two studies for analysis. Priorities of forehead feminization entail frontal bossing reduction, frontonasal angle widening, orbital contouring, brow lifting, and hairline advancement."｜caveat: 该研究之主题为面部女性化手术；本文仅引用其对「解剖目标与术式范畴」之描述，未引用任何人群特定之适应证结论。
  • F41｜来源#13｜confidence: low｜basis: peer_reviewed（PMID 38858245）｜geo: universal｜period: 2024-09｜claim: 其机构队列纳入 85 位患者，其中 92% 属第三型额部分类，额骨前板之平均计划后退量为 4.12 毫米；该期刊要求之证据等级自评为第三级。｜span: "Eighty-five patients were included for analysis. The majority were of Caucasian race (56%) and had type 3 forehead classification (92%). The average planned setback of the anterior table was 4.12 mm." 与 "LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article."｜caveat: 对象为跨性别女性之面部女性化手术队列，人群特定；分型分布与后退量不可外推为一般人之手术参数，本文仅用以说明处置的解剖目标与量级概念。
  • F42｜来源#14｜confidence: medium｜basis: peer_reviewed（PMID 35934514，术式综述）｜geo: universal｜period: 2022-08｜claim: 睪固酮造成上脸部多项特征变化，包含发际线上移与方形化、中央额部变平，以及眉骨与眶缘之前突增加。｜span: "These changes include elevating and squaring the hairline, flattening the central forehead, and increasing the anterior projection of the brow bone and orbital rims."｜caveat: 为叙述性术式综述之背景陈述，非流行病学或因果研究；本文未引用其任何术式效果宣称。
  • F43｜来源#15｜confidence: medium｜basis: peer_reviewed（PMID 41161936，影像学综述）｜geo: universal｜period: 2025-11｜claim: 颞下颌关节出现模仿囊肿与肿瘤之透射性与阻射性病变属罕见；骨内病变包含皮质下假性囊肿、动脉瘤性骨囊肿与单纯性骨囊肿，关节腔内病变则包含滑膜与腱鞘囊肿，以及滑膜软骨瘤病与焦磷酸钙沉积等钙化性病变。｜span: "Radiolucent and radiopaque lesions of the temporomandibular joints (TMJs) mimicking cysts and tumors are rare. Some lesions in the TMJ complex are intraosseous, while others are in the joint spaces. Intraosseous lesions include cyst-like lesions, for example, subcortical pseudocysts, aneurysmal bone cysts, and simple bone cysts. Lesions in the joint spaces include low-density synovial and ganglion cysts and calcified entities such as synovial chondromatosis and calcium pyrophosphate deposits."｜caveat: 为影像学综述之类别列举，未提供发生率；本文引用其作为「罕见但存在、需影像鉴别」之依据，不作任何诊断指示。
  • F44｜来源#16｜confidence: medium｜basis: peer_reviewed（PMID 31675112，叙述性综述）｜geo: universal｜period: 2020-01｜claim: 牙痛与颞下颌关节紊乱病、原发性头痛、创伤后三叉神经病变等状况会互相模仿；该区域解剖复杂、鉴别诊断庞大，加上各专科训练分立，导致诊断错误与延误，并常使患者接受不适当的外科与内科治疗。｜span: "The anatomical complexity of the region, the potential exhaustive differential diagnoses and the multiple siloed training of specialties, leads to incorrect and delayed diagnosis and often results in patients undergoing inappropriate surgical and medical treatments."｜caveat: 叙述性综述，非系统综述或试验；为领域层级之现象评述，不含任何发生率数字。
  • F45｜来源#16｜confidence: medium｜basis: peer_reviewed（PMID 31675112）｜geo: universal｜period: 2020-01｜claim: 该综述指出，许多患者被开立无数疗程的抗生素并接受多次外科介入，仅因专科训练分立造成的教育不足；作者主张此问题必须被处理以提升患者安全。｜span: "Many patients are prescribed countless courses of antibiotics and undergo multiple surgical interventions simply as a result of poor education due to siloed specialty training. This must be addressed to improve patient safety."｜caveat: 为作者之评述性主张，非量化证据；本文引用其作为「厘清诊断前避免不可逆处置」之依据。
  • F46｜来源: 本站编务判断｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 本文的分类地图、处置阶梯与红旗整理为沟通用结构，非诊断工具，亦非任何个人的治疗计划；本文不提供任何自行复位、自行用药或自我诊断之操作方法。｜caveat: 属编辑框架声明，不承载医学事实主张。
  • F47｜来源: 本站编务判断｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 本文费用段落仅说明成本组成与影响因素（诊断路径、人力与疗程长度、是否加做影像、术式取向、随访长度），不提供任何金额，亦不涉及任一国之给付制度。｜caveat: 属编辑框架声明；影响因素之临床依据逐项挂于对应 F-Unit。
  • F48｜来源: 本站编务判断｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 本次以 PubMed E-utilities 检索（检索式含 temporomandibular disorders clinical practice guideline、conditions mimicking temporomandibular disorders differential diagnosis、red flags orofacial pain serious pathology 等）未取得可引用之完整 TMD 红旗判定标准研究；本文红旗节仅列出既有来源能支持之情境，非穷尽清单。｜caveat: 「未取得」不等于「已被推翻」；本栏为编辑性陈述，不得标为待验 claim。
  • F49｜来源: 本站编务判断｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 本文为领域层文章，具体题目的答案由对应正典卡负责；本文仅摘述并指路，不重写卡片内容，亦不宣称任何卡片已发布。｜caveat: 属编辑框架声明；各卡状态以其档案 status 栏为准。
  • F50｜来源: 本站编务判断（依 F30、F31、F40、F41、F42）｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 依文献所述之解剖目标区分科别界线：正颌手术之目标为上下颌骨位置关系与咬合（F30、F31），额部与眉骨处置之目标为额骨前板、额鼻角、眶缘与发际线且与齿列咬合无关（F40 至 F42），且后者之文献分别发表于整形外科与耳鼻喉头颈／面部整形领域期刊；故眉骨突出之处置与一般牙科的咬合处置不是同一件事，通常需另行评估与转诊。｜caveat: 属依既有来源所作之编辑性归纳，非任一来源之原文结论；本条仅能支持「解剖目标为何」与「文献发表于哪些领域」两件事，不能支持「由哪一个专科执行」，故正文与 FAQ 一律不得写成「而非牙科」等排除式结论；实际转诊与分科由临床判定，部分地区之颅面与口腔颌面外科团队同样承接额部处置。
  • F51｜来源: 本站编务判断｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 本篇 geo_scope 为 global，全部医学宣称锚定国际文献与学会指南，不引用任一国之法规、保险给付与收费制度；在地制度与费用请见对应在地正典卡。｜caveat: 属编辑框架声明；在其他地区就诊时，制度面请以当地规定为准。
  • F52｜来源: 本站编务判断｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 本次检索未取得可引用之、系统性整理的颞下颌与正颌处置禁忌证清单文献，因此本文不提供禁忌证列表；禁忌证之个别判定须由医师依全身状况、用药史与影像评估决定。｜caveat: 「未取得」不等于「不存在」；本栏为证据缺口声明，不得标为待验 claim。
  • F53｜来源: 本站编务判断（关于来源#11 之证据边界）｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 本文所引之正颌手术量化结果（ANB 改善、骨性稳定比例、整体并发症率、感觉神经异常比例、复发比例、生活质量与满意度）全部来自单一篇系统综述（来源#11，2026 年发表）；本次检索未取得可交叉验证同组指目标第二篇系统综述，故上述数字应读为单一来源之汇总值，非跨研究一致之定论。｜caveat: 属证据边界声明；不得因「有数字」而视为高确定性，亦不得改写为任何个人可预期之结果。
  • F54｜来源#8｜confidence: low｜basis: peer_reviewed（PMID 29556163，11 例病例回顾）｜geo: universal｜period: 2017-12｜claim: 在该 11 例病例回顾中，病因为外伤者 4 例、大幅张口者 6 例、不明者 1 例；作者于结论将「大幅张口为病因」列为该院颞下颌关节脱位型态的特征之一。｜span: "Aetiology was trauma in 4 cases, wide mouth opening in 6 cases and unknown in a patient." 与 "The pattern of presentation of TMJ dislocation in the above named hospital was anterior dislocation, the female gender predominance, aetiology of wide mouth opening, as well as early presentation."｜caveat: 单中心、11 例，样本极小，不得作为人群病因分布之估计；本条之作用是与 F23（文献汇总之外伤 60%）并读，呈现两来源不一致，不用以推翻 F23，亦不得反向用以推翻本条。
  • span: "Case review of 11 patients with TMJ dislocation seen in the University College Hospital (UCH) Ibadan over a period of 10 years."
  • F55｜来源#8｜confidence: low｜basis: peer_reviewed（PMID 29556163）｜geo: universal｜period: 2017-12｜claim: 该综述记录，慢性病例中以 Hippocrates 手法成功处理者为 50%。｜span: "Fifty percent of the chronic cases were successfully managed with the Hippocrates manoeuvre."｜caveat: 该系列之慢性病例仅 2 例（原文 "There were 7 acute presentations, 2 recurrences and 2 chronic presentations"），50% 即 1 例，比例之信息量极低；本条之作用是避免只引用 F26 之作者结论句而略去同段方向不一致的数据，不得用以宣称任何成功率。

扩节新增：非牙源性口颌面疼痛（F56–F83，2026-08-06）

  • F56｜来源#17｜confidence: medium｜basis: peer_reviewed（PMID 41238336，叙述性综述）｜geo: universal｜period: 2026-01｜claim: 非牙源性牙痛是非牙齿来源的牙痛，其病因包含但不限于肌筋膜、心脏、神经血管、三叉神经痛、鼻窦来源、感染、药物、全身状况与心因性。｜span: "Nonodontogenic toothaches (NOTAs) are toothaches of nondental origin with etiologies including but not limited to myofascial, cardiac, neurovascular, trigeminal neuralgia, sinus origin, infections, drugs, systemic conditions, and psychogenic."｜caveat: 为叙述性综述之范围界定，未提供各病因之发生率；不得由此清单推导任何个人的病因排序。
  • F57｜来源#17｜confidence: medium｜basis: peer_reviewed（PMID 41238336）｜geo: universal｜period: 2026-01｜claim: 重现患者主诉的熟悉痛感对非牙源性牙痛的诊断至为关键；疼痛的部位与来源是不同的两件事。｜span: "Reproduction of the patient's chief complaint/familiar pain is crucial for the diagnosis of NOTAs. The site and source of pain are different."｜caveat: 为诊断原则之陈述，非可自行操作的检查方法；本文不提供任何自我测试步骤。
  • F58｜来源#17｜confidence: medium｜basis: peer_reviewed（PMID 41238336）｜geo: universal｜period: 2026-01｜claim: 非牙源性牙痛因表现为牙痛而构成真实的诊断挑战，使患者接受不必要且不可逆的治疗；故完整的病史（含旅游史）、临床检查、影像、实验室检查与诊断性及药理性测试对正确诊断至为关键，并应接续跨领域的处置取向。｜span: "NOTAs can pose a real diagnostic challenge due to its presentation as a toothache, rendering unnecessary and irreversible treatment of the patients." 与 "a thorough medical and travel history, clinical examination, imaging, laboratory investigations, diagnostic and pharmacologic testing are crucial for accurate diagnosis followed by an interdisciplinary management approach"｜caveat: 「诊断性及药理性测试」为原文 diagnostic and pharmacologic testing 之对译，属临床端处置，本文不描述其操作内容，亦不作任何用药指示。
  • F59｜来源#18｜confidence: high（对书目事实本身）｜basis: peer_reviewed（PMID 32103673）｜geo: universal｜period: 2020-02｜claim: 国际口颌面疼痛分类第 1 版（ICOP）于 2020 年 2 月发表于 Cephalalgia。｜span: "International Classification of Orofacial Pain, 1st edition (ICOP)"｜caveat: 该笔 PubMed 记录仅有书目资料、无摘要，本站仅能逐字引用其标题；ICOP 的定义与内容一律经由来源#19、#20、#30 等可取回摘要之转引呈现，本文未对 ICOP 正文作任何逐字引用。
  • F60｜来源#19｜confidence: medium｜basis: peer_reviewed（PMID 36404082，临床综述）｜geo: universal｜period: 2023-01｜claim: 该综述引述 ICOP 对特发性疼痛的描述为：单侧或双侧的口内或面部疼痛，位于三叉神经一或多个分支的分布区，病因不明；疼痛通常持续、中等强度、定位不清，被描述为钝痛、压迫感或灼热感。ICOP 特发性疼痛节所收的诊断包含灼口综合征与持续性特发性面部及牙槽疼痛。｜span: "unilateral or bilateral intraoral or facial pain in the distribution(s) of one or more branches of the trigeminal nerve(s) for which the etiology is unknown. Pain is usually persistent, of moderate intensity, poorly localized and described as dull, pressing or of burning character." 与 "Several diagnoses are included in the ICOP Idiopathic pain section, burning mouth syndrome and persistent idiopathic facial and dentoalveolar pain."｜caveat: 为该综述对 ICOP 之转引，非 ICOP 正文逐字引用（ICOP 正文未取回，见 F59）；该文标题所提之「中枢性疼痛疾患」为作者提问，本文未引用其任何机制主张。
  • F61｜来源#20｜confidence: medium｜basis: peer_reviewed（PMID 35574619，叙述性综述）｜geo: universal｜period: 2022-06-12｜claim: 该综述逐字引述 ICOP 2020 对灼口综合征的定义：特发性口颌面疼痛，口内灼热或感觉异常，每日复发超过 2 小时且持续超过 3 个月，无任何可辨识的致病病灶，可伴或不伴体感觉变化；并记载全球患病率于人群研究中估计为 1.73%，女性与高龄者风险较高。｜span: "idiopathic orofacial pain with intraoral burning or dysesthesia recurring daily for more than 2 hours per day and more than 3 months, without any identifiable causative lesions, with or without somatosensory changes" 与 "Worldwide prevalence of BMS was estimated to be 1.73% in population-based studies, while female and elderly are at higher risk of BMS."｜caveat: 叙述性综述，非系统综述；其所引之 1.73% 与来源#22 同源，两者不得重复计数为两份独立证据。
  • F62｜来源#21｜confidence: medium｜basis: peer_reviewed（PMID 40815383，叙述性综述）｜geo: universal｜period: 2025-09｜claim: 灼口综合征是以口腔黏膜持续灼热感、且无可见临床征象为特征的慢性疼痛状况；区分原发性（特发性）与续发性（与可辨识的潜在状况相关）之灼口综合征，对引导治疗至为关键。｜span: "Burning mouth syndrome (BMS) is a chronic pain condition characterized by a persistent burning sensation in the oral mucosa in the absence of visible clinical signs." 与 "Differentiating between primary (idiopathic) and secondary (associated with identifiable underlying conditions) BMS is critical for guiding treatment."｜caveat: 该文为叙述性综述，其摘要另列举多类药物与非药物选项，本文一律不引用其任何疗效陈述，亦不列出药名于正文；原发／续发之个别判定属临床评估，本文不提供判定清单。
  • F63｜来源#22｜confidence: medium｜basis: peer_reviewed（PMID 33818878，系统综述与荟萃分析）｜geo: universal｜period: 2022-09｜claim: 该综述纳入 18 篇文献，合并估计灼口综合征患病率于一般人群为 1.73%、于临床患者为 7.72%；性别亚组分析显示女性（1.15%）高于男性（0.38%），年龄亚组分析显示 50 岁以上（3.31%）高于 50 岁以下（1.92%）。｜span: "Eighteen articles were included. The overall pooled prevalence of burning mouth syndrome was 1.73% (95% CI = 0.176-0.351, n = 26,632) in general population, and 7.72% (95% CI = 0.434-0.691, n = 86,591) in clinical patients." 与 "The subgroup analysis by gender showed the prevalence of female (1.15%) was higher than male (0.38%) in general population. The subgroup analysis by age showed the prevalence was higher for people over 50 (3.31%) than under 50 (1.92%)."｜caveat: 原文所报之 95% CI（0.176-0.351 与 0.434-0.691）与其百分比点估计的量级不一致（原文如此）；本文因此只引用点估计，不引用、不换算、不推测该区间。人群层级估计非个人风险。
  • F64｜来源#23｜confidence: medium｜basis: peer_reviewed（PMID 38155008，系统综述与荟萃分析）｜geo: universal｜period: 2024-02｜claim: 该综述以国际头痛学会现行分类（ICHD-3 与 ICOP）为准，自 4,252 篇文献纳入 41 篇；合并结果显示患者以女性居多、年龄集中于原文所称的第六与第七个十年，灼热感与舌部为出现频率居前的描述与部位；并显示灼口综合征与焦虑（P = .0006）、忧郁（P = .004）及口腔卫生不良（P = .00001）之间存在显著关联。｜span: "Of the 4,252 studies identified, 41 were included." 与 "Studies were pooled in meta-analyses and showed a significant prevalence of female patients between the sixth and seventh decade of life. The burning sensation and the tongue were the most prevalent descriptors and affected location." 与 "Significant associations were demonstrated between BMS and anxiety (P = .0006), depression (P = .004), and poor oral hygiene (P = .00001)."｜caveat: 关联不等于因果，原文亦未判定方向；「第六与第七个十年」为 sixth and seventh decade of life 之对译，本文不代为换算年龄区间；「出现频率居前」为 most prevalent 之对译，不代表诊断依据。
  • F65｜来源#24｜confidence: high｜basis: peer_reviewed（PMID 27855478，Cochrane 系统综述）｜geo: universal｜period: 2016-11-18｜claim: 灼口综合征一词指的是找不到可辨识原因的口腔黏膜疼痛（舌、唇或整个口腔的灼痛或不适）；一般人群患病率自 0.1% 至 3.9% 不等；许多灼口综合征患者有焦虑、忧郁、人格疾患与生活质量受损。｜span: "Burning mouth syndrome (BMS) is a term used for oral mucosal pain (burning pain or discomfort in the tongue, lips or entire oral cavity) without identifiable cause. General population prevalence varies from 0.1% to 3.9%." 与 "Many BMS patients indicate anxiety, depression, personality disorders and impaired quality of life (QoL)."｜caveat: 为 Cochrane 之背景段陈述；共病为描述性关联，未提供因果方向；本条之患病率区间与来源#22 之合并估计口径不同，不得合并或互相取代。
  • F66｜来源#24｜confidence: high｜basis: peer_reviewed（PMID 27855478）｜geo: universal｜period: 2016-11-18｜claim: 该综述纳入 23 篇随机对照试验（1,121 位分析对象，其中 83% 为女性）；仅 1 篇整体评为低偏倚风险、4 篇偏倚风险不明、18 篇高偏倚风险；对全部介入与全部结果而言，有效性的整体证据质量皆为极低。｜span: "We included 23 RCTs (1121 analysed participants; 83% female)." 与 "Only one RCT was assessed at low risk of bias overall, four RCTs' risk of bias was unclear, and 18 studies were at high risk of bias." 与 "Overall quality of the evidence for effectiveness was very low for all interventions and all outcomes."｜caveat: 「证据质量极低」为 GRADE 用语，指对效果估计的信心极低，非指介入本身有害；检索截止为 2015-12-31，故较新试验未纳入（见来源#25）。
  • F67｜来源#24｜confidence: high（对结论措辞本身）｜basis: peer_reviewed（PMID 27855478）｜geo: universal｜period: 2016-11-18｜claim: 该综述作者结论为：由于低偏倚风险的临床试验数量有限，证据不足以支持或反对在灼口综合征处置中使用任何介入。｜span: "Due to the limited number of clinical trials at low risk of bias, there is insufficient evidence to support or refute the use of any interventions in managing BMS."｜caveat: 「证据不足」不等于「无效」，亦不等于「不应处置」；本条不得被改写为对任何介入的否定或肯定宣称。
  • F68｜来源#25｜confidence: medium｜basis: peer_reviewed（PMID 36214096，系统综述与网络荟萃分析，PROSPERO CRD42021255039）｜geo: universal｜period: 2023-02｜claim: 该网络荟萃分析纳入 44 篇试验（其中 24 篇进入网络分析）；在全部受测治疗中，只有一种抗焦虑类药物（原文 clonazepam）在与安慰剂比较时可能降低灼口综合征疼痛（平均差 −1.88，95% CI −2.61 至 −1.16，中等确定性）；其余多数治疗为低与极低确定性，主因为不精确、间接性与不可传递性。｜span: "Forty-four trials were included (24 in the NMA). The anxiolytic (clonazepam) probably reduces the pain of BMS when compared with placebo (MD, -1.88; 95% CI, -2.61 to -1.16; moderate certainty)." 与 "Among all tested treatments, only clonazepam is likely to reduce the pain of BMS when compared with placebo. The majority of the other treatments had low and very low certainty, mainly due to imprecision, indirectness, and intransitivity."｜caveat: 药品名称仅出现于本 span 之原文，本文正文不对任何药品作疗效陈述、剂量、用法或停药指示；「中等确定性」为 GRADE 用语，非疗效承诺；原文另记载光生物调节与另一种药物达到其所定义的 minimal important difference 门槛、但确定性为低或极低，本文未引用该部分以免高估证据强度。
  • F69｜来源#26｜confidence: high｜basis: clinical_guideline（PMID 30860637，PubMed 文献类型标示 Practice Guideline）｜geo: universal｜period: 2019-06｜claim: 该指南建议采用最新分类系统，将三叉神经痛诊断为原发性（依神经血管接触程度分为典型或特发性）或由神经血管接触以外之病理所致之续发性；并建议以磁共振成像（三种高分辨率序列之组合）作为检查工作的一部分，因为没有任何临床特征可以排除续发性三叉神经痛。｜span: "The use of the most recent classification system is recommended, which diagnoses TN as primary TN, either classical or idiopathic depending on the degree of neurovascular contact, or as secondary TN caused by pathology other than neurovascular contact." 与 "Magnetic resonance imaging (MRI), using a combination of three high-resolution sequences, should be performed as part of the work-up in TN patients, because no clinical characteristics can exclude secondary TN."｜caveat: 本站仅取回 PubMed 摘要，指南正文未取回，不作正文逐字引用；影像术式与时机属临床决定，本文不指定任何检查项目给个人。
  • F70｜来源#26｜confidence: high｜basis: clinical_guideline（PMID 30860637）｜geo: universal｜period: 2019-06｜claim: 该指南记载在欧洲三叉神经痛患者由许多不同专科处置；建议若疼痛未获药物充分控制或药物耐受不良则提供手术，典型三叉神经痛之一线手术为微血管减压术；并建议于医疗与手术处置之外提供心理与护理支持。｜span: "In Europe, TN patients are managed by many different specialities." 与 "It is recommended that patients should be offered surgery if pain is not sufficiently controlled medically or if medical treatment is poorly tolerated. Microvascular decompression is recommended as first-line surgery in patients with classical TN." 与 "In addition to medical and surgical management, it is recommended that patients are offered psychological and nursing support."｜caveat: 「由许多不同专科处置」为该指南对欧洲现况之描述，不得被读为任何地区之分科规定；手术之适应证、并发症与禁忌证不在本摘要范围，本文不作任何手术推荐。
  • F71｜来源#26｜confidence: high｜basis: clinical_guideline（PMID 30860637）｜geo: universal｜period: 2019-06｜claim: 该指南建议三叉神经痛之长期治疗以两种特定口服处方药为一线用药（原文为 carbamazepine 或 oxcarbazepine）。｜span: "For long-term treatment, carbamazepine or oxcarbazepine are recommended as drugs of first choice."｜caveat: 药品名称仅出现于本 span 之原文，且原文摘要未载明其药理类别，故本文正文不作任何药物类别归属；处方属医师范围，本文不提供任何剂量、用法、加减量或停药指示，亦不对药品作疗效宣称。
  • F72｜来源#27｜confidence: medium｜basis: peer_reviewed（PMID 36404084，临床综述）｜geo: universal｜period: 2023-01｜claim: 三叉神经痛是一种罕见的神经病理性疼痛疾患，特征为反复、阵发、短时间持续的重度电击样疼痛，沿三叉神经之感觉分布区出现；近期的分类系统依潜在病理生理将其分为三大类。｜span: "Trigeminal neuralgia (TN) is a rare neuropathic pain disorder characterized by recurrent, paroxysmal episodes of short-lasting severe electric shock-like pain along the sensory distribution of the trigeminal nerve." 与 "Recent classification systems group TN into 3 main categories depending on the underlying pathophysiology."｜caveat: 为叙述性临床综述之定义段，未提供发生率数字；特征描述不是自我诊断标准，符合描述不等于即为此诊断。
  • F73｜来源#28｜confidence: low｜basis: peer_reviewed（PMID 33408940，回顾性问卷研究）｜geo: universal｜period: 2020-12-22｜claim: 该研究对两家机构 2010 至 2019 年间接受伽玛刀放射手术之 187 位三叉神经痛患者发问卷，117 位回复；其中 55.5% 曾以牙痛表现、65.8% 曾因该疼痛就诊牙医；41.8% 接受过一项牙科处置，18.8% 疼痛恶化、8.5% 得到部分改善；19.6% 接受过根管治疗、6.8% 接受过神经阻滞；平均每人被拔除 1.6 颗牙。｜span: "One hundred and seventeen of the 187 patients responded. About 55.5% of patients had a toothache and 65.8% did visit a dentist for the pain." 与 "About 41.8% of patients underwent one dental procedure; 18.8% suffered from worsening of the pain while 8.5% received some partial improvement. About 19.6% also underwent root canal treatment while 6.8% had a nerve block. Mean of 1.6 teeth was extracted per person."｜caveat: 回顾性问卷、单一处置人群（已转诊至神经外科并接受伽玛刀者），存在选择与回忆偏倚，回复率 117/187；上述比例不得外推为所有三叉神经痛患者、更不得外推为一般牙科就诊人群之比例；本条仅支持「此误诊路径存在且代价不可逆」之方向性结论。原文各比例前均冠以 About（约），本文正文为行文简洁未逐一加注，引用时应理解为近似值；「平均每人被拔除 1.6 颗牙」一项，原文未载明其分母为全体回复者或仅曾接受拔牙者，故不得据此推算被拔牙人数。
  • F74｜来源#28｜confidence: medium（对结论措辞本身）｜basis: peer_reviewed（PMID 33408940）｜geo: universal｜period: 2020-12-22｜claim: 该研究结论为：需要牙医与患者对此疾病有更好的理解，以达成及时且正确的治疗而不失去牙齿；作者并指出向外传递正确诊断与治疗方式知识的责任在神经外科与神经内科。｜span: "There is a need for a better understanding of the disease among the dentists and the patients for the timely and correct treatment, without losing their teeth." 与 "The onus lies on neurosurgeons/neurologists disseminate knowledge regarding proper diagnosis and treatment modalities."｜caveat: 为作者之评述性主张，非量化证据；原文句法有语法瑕疵（disseminate 未变化），span 保留原文供查核；本条不得被读为任何地区之转诊规定。
  • F75｜来源#29｜confidence: medium｜basis: peer_reviewed（PMID 29174443，综合性综述）｜geo: universal｜period: 2018-02｜claim: 特发性来源之持续性牙槽疼痛对牙医与医师同样构成诊断挑战；命名分类与诊断标准缺乏共识，明显限制该领域研究的推进；患者面对的是牙科与医界专业知识不足、诊断延误与不必要的治疗。｜span: "Persistent dentoalveolar pain of idiopathic origin represents a diagnostic challenge for the dentist and physician alike. Disagreement on taxonomy and diagnostic criteria presents a significant limit to the advancement of research in the field." 与 "Patients struggle with a lack of knowledge by dental and medical professionals, diagnostic delays, and unnecessary treatments."｜caveat: 为叙述性综合性综述之现况评述，不含发生率或风险数字；不得由本条推导任何医疗责任归属之结论。
  • F76｜来源#29｜confidence: medium｜basis: peer_reviewed（PMID 29174443）｜geo: universal｜period: 2018-02｜claim: 该综述检索所用的同义与相邻名称包含非典型牙痛、幻牙痛、持续性特发性面痛、疼痛性创伤后三叉神经病变、特发性牙痛、持续性牙槽疼痛疾患、非牙源性牙痛与持续性神经病理性口颌面疼痛；可得文献以病例报告与叙述性综述为主，治疗策略仅在 7 篇开放标签研究与 2 篇随机对照试验中被评估。｜span: "atypical odontalgia, phantom tooth pain, persistent idiopathic facial pain, painful posttraumatic trigeminal neuropathy, idiopathic toothache, persistent dentoalveolar pain disorder, nonodontogenic tooth pain, and continuous neuropathic orofacial pain" 与 "Case reports and narrative reviews constitute the majority of available literature." 与 "Treatment strategies were evaluated in only 7 open-label and 2 randomized controlled trials."｜caveat: 检索截止为 2017-01-01，较新文献未纳入；上列名称为文献检索词，不等于它们是同一个诊断，各名称之标准差异正是该文所指的共识缺口。
  • F77｜来源#29｜confidence: medium（对结论措辞本身）｜basis: peer_reviewed（PMID 29174443）｜geo: universal｜period: 2018-02｜claim: 该综述结论为：持续性牙槽疼痛疾患的成因可能是神经病理性的，但解释其发生与持续的病理生理机制仍远未被理解；在施行治疗之前，应先确立正确的诊断。｜span: "Persistent dentoalveolar pain disorder is likely neuropathic in origin, but pathophysiological mechanisms to explain the onset and persistence of the pain are still far from understood. A correct diagnosis should be established before treatments are performed."｜caveat: 「先确立诊断再治疗」为综述层级之临床原则，未指定任何诊断方法、时程或门槛；本文据此仅推出「诊断未确立前避免不可逆处置」之方向。
  • F78｜来源#30｜confidence: medium｜basis: peer_reviewed（PMID 34792207，观察性研究）｜geo: universal｜period: 2022-03｜claim: 该研究逐字引述 ICOP 6.3 对持续性特发性牙槽疼痛（PIDAP）的定义：持续性单侧口内牙槽疼痛，少见于多个部位，特征多变但每日复发超过 2 小时、持续超过 3 个月，且不存在任何先前的致病事件。｜span: "Persistent unilateral intraoral dentoalveolar pain, rarely occurring in multiple sites, with variable features but recurring daily for more than 2 h per day for more than 3 months, in the absence of any preceding causative event"｜caveat: 为该研究对 ICOP 之转引（ICOP 正文未取回，见 F59）；PIDAP 为排除性诊断，本文不提供任何自我判定方法。
  • F79｜来源#30｜confidence: low｜basis: peer_reviewed（PMID 34792207）｜geo: universal｜period: 2022-03｜claim: 该观察性研究于转诊制之根管治疗专科诊所评估 160 位患者，其中 78 位（63 位女性）符合严格之 PIDAP 标准；69% 的 PIDAP 患者其疼痛与同部位已做过根管治疗之牙齿相关，14% 的病例在患侧象限未曾接受任何根管治疗；85% 无夜间痛醒；另在「有疼痛牙齿或种植体之患者」中 91% 于龈沟出现机械性触诱发痛。｜span: "Amongst the 160 patients assessed, 78 (63 women) fulfilled the strict PIDAP criteria." 与 "In 69% of the patients with PIDAP, pain was associated with a root filled tooth at the same site. In 14% of the cases, no endodontic treatment was performed in the affected quadrant." 与 "Mechanical allodynia in the gingival sulcus was observed in 91% of patients with painful teeth or implants." 与 "Pain history of PIDAP included no nocturnal awakening (85%) and a 'pulling/dragging' pain quality (59%)."｜caveat: 单一转诊制专科诊所之回顾资料（涵盖 16 年），人群高度选择性，比例不得外推为一般人群或一般牙科就诊人群；上列特征为该人群之描述性分布，不是诊断标准，符合特征不等于即为此诊断；91% 一项的原文分母为 "patients with painful teeth or implants"，与前三项的 PIDAP 患者分母不完全相同，禁合并叙述为「91% 的 PIDAP 患者」。
  • F80｜来源#31｜confidence: medium｜basis: peer_reviewed（PMID 20113779，系统综述与荟萃分析）｜geo: universal｜period: 2010-02｜claim: 该研究将根管治疗后持续性牙痛定义为治疗后 6 个月以上仍存在之疼痛（不论病因）；自 770 篇文献纳入 26 篇，共 5,777 颗牙、其中 2,996 颗有疼痛状态随访资料，168 颗有疼痛，合并估计为 5.3%（95% CI 3.5% 至 7.2%）；研究间异质性高且具统计学显著性（I² = 80%）；亚组分析中前瞻性研究之疼痛频率（7.6%）高于回顾性研究（0.9%）。｜span: "Persistent tooth pain was defined as pain present > or = 6 months after endodontic treatment." 与 "Of 770 articles retrieved and reviewed, 26 met inclusion criteria. A total of 5,777 teeth were enrolled, and 2,996 had follow-up information regarding pain status." 与 "We identified 168 teeth with pain and derived a frequency of 5.3% (95% confidence interval, 3.5%-7.2%, p < 0.001) for persistent all-cause tooth pain." 与 "High and statistically significant heterogeneity among studies (I2 = 80%) was present." 与 "In subgroup analysis, prospective studies had a higher pain frequency (7.6%) than retrospectives studies did (0.9%)."｜caveat: 「所有原因之持续疼痛」包含各种病因，不等于特发性疼痛之比例；异质性极高且前瞻／回顾差距达一个数量级，本数字仅为量级概念，不得作为个人概率或疗效指标；发表于 2010 年，较新资料未纳入。
  • F81｜来源: 本站编务判断（依 F8、F16、F59、F60）｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 本文第一至第三节属 DC/TMD 分类与其慢性 TMD 疼痛处置阶梯，本扩节属 ICOP 特发性疼痛与神经痛体系；两者分类架构与证据体系不同，不得互相套用。本文不做任何症状到诊断的对号入座，亦不提供自我判定方法；症状分级与就诊分流之具体判定标准由对应领域文与正典卡负责，本文只摘述指路、不重写其内容。｜caveat: 属编辑框架声明，不承载医学事实主张；两体系可并存于同一位患者，本条仅禁止机械互推，非宣称两者互斥。
  • F82｜来源: 本站编务判断（依 F66、F67、F68、F70、F71）｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 本扩节所引之处置证据，其证据层级以 Cochrane 系统综述与网络荟萃分析为上限，两者均自陈证据确定性为极低至中等或证据不足；本文因此不对任何处置作有效性宣称，不列出任何药品名称于正文，亦不提供剂量、用法或停药指示；所有处置之适用与否须由医师个别判定。｜caveat: 属证据边界与合规声明；「证据不足」不等于「无效」，本条不得被读为对任何处置的否定。
  • F83｜来源: 本站编务判断｜confidence: n/a｜basis: editorial_framework｜geo: universal｜period: 2026-08-06｜claim: 本次以 PubMed E-utilities 检索（检索式含 nonodontogenic toothache differential diagnosis、burning mouth syndrome systematic review、trigeminal neuralgia guideline、persistent idiopathic dentoalveolar pain 等）未取得可引用且经验证之非牙源性口颌面疼痛红旗判定标准工具；本文第十一节仅列出既有来源能支持之情境，非穷尽清单。｜caveat: 「未取得」不等于「已被推翻」或「不存在」；本栏为编辑性陈述，不得标为待验 claim。

合规注记

本文为卫生教育信息，非医疗广告，不推荐特定医疗机构、不比较任何医师或机构、不提供任何金额 [F49]。颞下颌关节紊乱病之处置、下巴脱位之复位、正颌手术与颌面手术均具风险、适应证与禁忌证；本文已于「风险因素」节揭露可引用之并发症与证据缺口 [F32][F33][F34][F52]。实际治疗方式与效果因人而异，须由牙医评估；涉及骨性手术者，须由口腔颌面外科与口腔正畸专科团队共同评估 [F35][F46]。本文整理的分类地图与处置阶梯供就诊沟通使用，不能取代临床诊断，亦不能作为自我诊断或自行处置的依据 [F46]。文中所引之药品与注射处置名称，仅出现于指南原文之逐字 span，属研究与指南层级之陈述，本文不对任何药品或处置作疗效宣称或使用建议 [F14][F27]。2026-08-06 扩节补充：第九至十一节（非牙源性口颌面疼痛）同受上述各条拘束——该三节不对灼口综合征、三叉神经痛或持续性特发性面部／牙面痛的任何处置作有效性宣称，正文不出现药品名称（药名仅存于逐字 span 与 caveat），不提供剂量、用法或停药指示，也不提供任何自我诊断或自行处置的方法；其「该怀疑不是牙的问题」情境为就诊沟通用信号、非诊断标准，且非穷尽清单，未列出的情况不代表安全 [F82][F83][F46]。

来源清单

全部来源取用日期：2026-08-06（Asia/Taipei）。实测方式：PubMed E-utilities efetch（rettype=abstract、retmode=text）取回摘要全文，并以 `https://pubmed.ncbi.nlm.nih.gov//` 逐条 curl 回传 HTTP 200；全部 16 条均以 esummary 检查 PublicationType，无一条标示 Retracted Publication。

锚定档 `ida-pillars/anchors/P09-anchors.md` 之 #01（医疗法第 63 条）、#02（全民健康保险法第 51 条）、#03（健保署支付标准颌骨矫正手术给付规定）为台湾法规与官方来源。依 owner 2026-08-06 全线 global 定调，本篇一条都未采用，亦未列入本清单；涉在地制度之内容一律以下链句指向对应在地正典卡（由 F51 编辑框架 F-Unit 承载，以确保全部 F-Unit 之 geo 皆为 universal）。

  • S1｜clinical_guideline｜Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group. J Oral Facial Pain Headache. 2014 Winter;28(1):6-27.｜PMID 24482784｜DOI 10.11607/jop.1151｜https://pubmed.ncbi.nlm.nih.gov/24482784/ ｜取用 2026-08-06
  • S2｜clinical_guideline｜Busse JW, Casassus R, Carrasco-Labra A, et al. Management of chronic pain associated with temporomandibular disorders: a clinical practice guideline. BMJ. 2023 Dec 15;383:e076227.｜PMID 38101929｜DOI 10.1136/bmj-2023-076227｜https://pubmed.ncbi.nlm.nih.gov/38101929/ ｜取用 2026-08-06
  • S3｜textbook（国家科学院共识研究报告）｜National Academies of Sciences, Engineering, and Medicine. Temporomandibular Disorders: Priorities for Research and Care. Washington (DC): National Academies Press (US); 2020 Mar 12.｜PMID 32200600｜DOI 10.17226/25652｜https://pubmed.ncbi.nlm.nih.gov/32200600/ ｜取用 2026-08-06
  • S4｜peer_reviewed｜Valesan LF, Da-Cas CD, Réus JC, et al. Prevalence of temporomandibular joint disorders: a systematic review and meta-analysis. Clin Oral Investig. 2021 Feb;25(2):441-453.｜PMID 33409693｜DOI 10.1007/s00784-020-03710-w｜https://pubmed.ncbi.nlm.nih.gov/33409693/ ｜取用 2026-08-06
  • S5｜peer_reviewed｜Bijelic T, Michelotti A, Bucci R, et al. Self-Management Therapies for Temporomandibular Disorders-Evidence From Systematic Reviews. J Oral Rehabil. 2026 Jan;53(1):265-281.｜PMID 41058307｜DOI 10.1111/joor.70074｜https://pubmed.ncbi.nlm.nih.gov/41058307/ ｜取用 2026-08-06
  • S6｜peer_reviewed｜İşisağ Ö, Atasoy H, Yıldız S. Comparison of the effects of occlusal splint and Botox injections on the amount of mouth opening and chronic pain in individuals with temporomandibular disorders: a systematic review and meta-analysis. Aust Dent J. 2025 Jun;70(2):132-140.｜PMID 39953753｜DOI 10.1111/adj.13059｜https://pubmed.ncbi.nlm.nih.gov/39953753/ ｜取用 2026-08-06
  • S7｜peer_reviewed｜Akinbami BO. Evaluation of the mechanism and principles of management of temporomandibular joint dislocation. Systematic review of literature and a proposed new classification of temporomandibular joint dislocation. Head Face Med. 2011 Jun 15;7:10.｜PMID 21676208｜DOI 10.1186/1746-160X-7-10｜https://pubmed.ncbi.nlm.nih.gov/21676208/ ｜取用 2026-08-06
  • S8｜peer_reviewed｜Okoje VN, Aladelusi TO, Abimbola TA. Managing temporomandibular joint dislocation in Ibadan: a review of 11 cases. Ann Ib Postgrad Med. 2017 Dec;15(2):96-102.｜PMID 29556163｜https://pubmed.ncbi.nlm.nih.gov/29556163/ ｜取用 2026-08-06
  • S9｜peer_reviewed｜Hoppe A, Turosz N, Chęciński M, et al. Management of Recurrent Temporomandibular Joint Dislocation in Children: A Systematic Review. J Clin Med. 2025 Nov 6;14(21):7881.｜PMID 41227277｜DOI 10.3390/jcm14217881｜https://pubmed.ncbi.nlm.nih.gov/41227277/ ｜取用 2026-08-06
  • S10｜peer_reviewed｜Alhammadi MS, Almashraqi AA, Khadhi AH, et al. Orthodontic camouflage versus orthodontic-orthognathic surgical treatment in borderline class III malocclusion: a systematic review. Clin Oral Investig. 2022 Nov;26(11):6443-6455.｜PMID 36098813｜DOI 10.1007/s00784-022-04685-6｜https://pubmed.ncbi.nlm.nih.gov/36098813/ ｜取用 2026-08-06
  • S11｜peer_reviewed｜Ebenezer V, Ganesh P, Vinayagar M. Clinical outcomes, complications and impact on quality of life following orthognathic surgery: a systematic review. Front Oral Health. 2026 May 26;7:1790589.｜PMID 42273603｜DOI 10.3389/froh.2026.1790589｜https://pubmed.ncbi.nlm.nih.gov/42273603/ ｜取用 2026-08-06
  • S12｜peer_reviewed｜Jenwanichkul N, Keerativittayanun S, Suttapreyasri S, Pripatnanont P. Panoptic evaluation of maxillomandibular stability and quality of life after surgery-first approach versus conventional three-stage method in skeletal Class III orthognathic surgery-systematic review and meta-analysis. Int J Oral Maxillofac Surg. 2026 Jan;55(1):20-33.｜PMID 40360332｜DOI 10.1016/j.ijom.2025.04.003｜https://pubmed.ncbi.nlm.nih.gov/40360332/ ｜取用 2026-08-06
  • S13｜peer_reviewed｜Khetpal S, Dahoud F, Elias A, Sasson DC, Wolfe EM, Lee JC. Feminization of the Forehead: A Scoping Literature Review and Cohort Study of Transfeminine Patients. Aesthetic Plast Surg. 2024 Sep;48(18):3577-3588.｜PMID 38858245｜DOI 10.1007/s00266-024-04143-6｜https://pubmed.ncbi.nlm.nih.gov/38858245/ ｜取用 2026-08-06
  • S14｜peer_reviewed｜Rolfes B. Brow Bossing Reduction. Otolaryngol Clin North Am. 2022 Aug;55(4):785-795.｜PMID 35934514｜DOI 10.1016/j.otc.2022.04.003｜https://pubmed.ncbi.nlm.nih.gov/35934514/ ｜取用 2026-08-06
  • S15｜peer_reviewed｜Ahmad M, Gaalaas L. Imaging of Tumor-like and Cyst-like Lesions of the Temporomandibular Joints. Neuroimaging Clin N Am. 2025 Nov;35(4):517-526.｜PMID 41161936｜DOI 10.1016/j.nic.2025.06.005｜https://pubmed.ncbi.nlm.nih.gov/41161936/ ｜取用 2026-08-06
  • S16｜peer_reviewed｜Renton T. Tooth-Related Pain or Not? Headache. 2020 Jan;60(1):235-246.｜PMID 31675112｜DOI 10.1111/head.13689｜https://pubmed.ncbi.nlm.nih.gov/31675112/ ｜取用 2026-08-06

扩节补源：非牙源性口颌面疼痛（S17–S31，2026-08-06）

上段之「全部 16 条」指 S1–S16（原稿范围）；本回合扩节新增之 S17–S31 共 15 条，另行独立实测，记录见下方 WRITER-ADDED SOURCES 之扩节段。取用日期同为 2026-08-06（Asia/Taipei）。

  • S17｜peer_reviewed｜Thomas DC, Somaiya T, Ajayakumar A, Prabhakar V. Toothaches of Non-odontogenic Origin. Dent Clin North Am. 2026 Jan;70(1):209-224.｜PMID 41238336｜DOI 10.1016/j.cden.2025.07.013｜https://pubmed.ncbi.nlm.nih.gov/41238336/ ｜取用 2026-08-06
  • S18｜peer_reviewed（国际分类文件，保守以 peer_reviewed 收录）｜International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia. 2020 Feb;40(2):129-221.｜PMID 32103673｜DOI 10.1177/0333102419893823｜https://pubmed.ncbi.nlm.nih.gov/32103673/ ｜取用 2026-08-06
  • S19｜peer_reviewed｜Heir GM, Ananthan S, Kalladka M, Kuchukulla M, Renton T. Persistent Idiopathic Dentoalveolar Pain: Is It a Central Pain Disorder? Dent Clin North Am. 2023 Jan;67(1):71-83.｜PMID 36404082｜DOI 10.1016/j.cden.2022.07.006｜https://pubmed.ncbi.nlm.nih.gov/36404082/ ｜取用 2026-08-06
  • S20｜peer_reviewed｜Russo M, Crafa P, Guglielmetti S, Franzoni L, Fiore W, Di Mario F. Burning Mouth Syndrome Etiology: A Narrative Review. J Gastrointestin Liver Dis. 2022 Jun 12;31(2):223-228.｜PMID 35574619｜DOI 10.15403/jgld-4245｜https://pubmed.ncbi.nlm.nih.gov/35574619/ ｜取用 2026-08-06
  • S21｜peer_reviewed｜Sangalli L, Mirfarsi S, Kramer JM, Eisa E, Miller CS. Managing Burning Mouth Syndrome: Current and Future Directions. Drugs. 2025 Sep;85(9):1109-1131.｜PMID 40815383｜DOI 10.1007/s40265-025-02220-x｜https://pubmed.ncbi.nlm.nih.gov/40815383/ ｜取用 2026-08-06
  • S22｜peer_reviewed｜Wu S, Zhang W, Yan J, Noma N, Young A, Yan Z. Worldwide prevalence estimates of burning mouth syndrome: A systematic review and meta-analysis. Oral Dis. 2022 Sep;28(6):1431-1440.｜PMID 33818878｜DOI 10.1111/odi.13868｜https://pubmed.ncbi.nlm.nih.gov/33818878/ ｜取用 2026-08-06
  • S23｜peer_reviewed｜de Lima-Souza RA, Pérez-de-Oliveira ME, Normando AGC, et al. Clinical and epidemiological profile of burning mouth syndrome patients following the International Headache Society classification: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2024 Feb;137(2):119-135.｜PMID 38155008｜DOI 10.1016/j.oooo.2023.10.002｜https://pubmed.ncbi.nlm.nih.gov/38155008/ ｜取用 2026-08-06
  • S24｜peer_reviewed（Cochrane 系统综述）｜McMillan R, Forssell H, Buchanan JA, Glenny AM, Weldon JC, Zakrzewska JM. Interventions for treating burning mouth syndrome. Cochrane Database Syst Rev. 2016 Nov 18;11(11):CD002779.｜PMID 27855478｜DOI 10.1002/14651858.CD002779.pub3｜https://pubmed.ncbi.nlm.nih.gov/27855478/ ｜取用 2026-08-06
  • S25｜peer_reviewed｜Alvarenga-Brant R, Costa FO, Mattos-Pereira G, et al. Treatments for Burning Mouth Syndrome: A Network Meta-analysis. J Dent Res. 2023 Feb;102(2):135-145.｜PMID 36214096｜DOI 10.1177/00220345221130025｜https://pubmed.ncbi.nlm.nih.gov/36214096/ ｜取用 2026-08-06
  • S26｜clinical_guideline｜Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019 Jun;26(6):831-849.｜PMID 30860637｜DOI 10.1111/ene.13950｜https://pubmed.ncbi.nlm.nih.gov/30860637/ ｜取用 2026-08-06
  • S27｜peer_reviewed｜Khawaja SN, Scrivani SJ. Trigeminal Neuralgia. Dent Clin North Am. 2023 Jan;67(1):99-115.｜PMID 36404084｜DOI 10.1016/j.cden.2022.07.008｜https://pubmed.ncbi.nlm.nih.gov/36404084/ ｜取用 2026-08-06
  • S28｜peer_reviewed｜Tripathi M, Sadashiva N, Gupta A, et al. Please spare my teeth! Dental procedures and trigeminal neuralgia. Surg Neurol Int. 2020 Dec 22;11:455.｜PMID 33408940｜DOI 10.25259/SNI_729_2020｜https://pubmed.ncbi.nlm.nih.gov/33408940/ ｜取用 2026-08-06
  • S29｜peer_reviewed｜Malacarne A, Spierings ELH, Lu C, Maloney GE. Persistent Dentoalveolar Pain Disorder: A Comprehensive Review. J Endod. 2018 Feb;44(2):206-211.｜PMID 29174443｜DOI 10.1016/j.joen.2017.09.009｜https://pubmed.ncbi.nlm.nih.gov/29174443/ ｜取用 2026-08-06
  • S30｜peer_reviewed｜Sanner F, Sonntag D, Hambrock N, Zehnder M. Patients with persistent idiopathic dentoalveolar pain in dental practice. Int Endod J. 2022 Mar;55(3):231-239.｜PMID 34792207｜DOI 10.1111/iej.13664｜https://pubmed.ncbi.nlm.nih.gov/34792207/ ｜取用 2026-08-06
  • S31｜peer_reviewed｜Nixdorf DR, Moana-Filho EJ, Law AS, McGuire LA, Hodges JS, John MT. Frequency of persistent tooth pain after root canal therapy: a systematic review and meta-analysis. J Endod. 2010 Feb;36(2):224-30.｜PMID 20113779｜DOI 10.1016/j.joen.2009.11.007｜https://pubmed.ncbi.nlm.nih.gov/20113779/ ｜取用 2026-08-06

FAQ

颞下颌关节会咔咔响，一定要治疗吗？
**「有这个现象」不等于「需要治疗」。** 先讲本文能讲与不能讲的：分类架构把关节痛、关节盘移位、退行性关节病等列为不同的格，其中可复性关节盘移位是患病率居前的类别（成人与老年约 25.9%）[F5][F6]；但**本文引用的来源并未建立「声响对应哪一格诊断」的对照，因此本文不做这个对号入座** [F46]。实际属于哪一格、需不需要处置，须由临床评估判定，且临床标准对部分关节内疾患的效度不足以作临床诊断、仅能用于筛查 [F11]。另一件要一起读的事：前述临床指南的建议对象明确限定为慢性（持续 3 个月以上）的 TMD 相关疼痛，不适用于急性疼痛 [F16]。
顎関節がカクカク鳴りますが、必ず処置が必要ですか — **「その現象がある」ことは「処置が必要である」ことと同じではありません。** まず本記事が言えること、言えないことを述べます。分類の枠組みは関節痛、関節円板転位、変性関節疾患などを別々のマスとして挙げており、そのうち復位性関節円板転位は有病率が上位のカテゴリーです（成人・高齢者で約 25.9%）[F5][F6]。しかし**本記事が引用した出典は「音がどのマスの診断に対応するか」という対照表を作っていないため、本記事はこの当てはめを行いません** [F46]。実際にどのマスに属するのか、対応が必要かどうかは臨床評価によって判断されるものであり、しかも臨床基準は一部の関節内障害について臨床診断とするには妥当性が不十分で、スクリーニングにしか使えません [F11]。もう一つ併せて読むべきことがあります。先述の臨床ガイドラインの推奨対象は慢性（3 か月以上持続する）TMD 関連疼痛に明確に限定されており、急性の痛みには適用されません [F16]。
My temporomandibular joint clicks — does it have to be treated? — **"Having the phenomenon" is not the same as "needing treatment".** First, what this article can and cannot say: the classification framework places arthralgia, disc displacement and degenerative joint disease in separate cells, and among them disc displacement with reduction is the category with the highest prevalence (about 25.9% in adults and older adults) [F5][F6]; but **the sources cited here establish no mapping from a sound to a diagnostic cell, so this article does not make that assignment** [F46]. Which cell it actually falls into, and whether anything needs doing, must be judged by clinical assessment, and the clinical criteria lack sufficient validity for some intra-articular disorders to serve as clinical diagnoses and can be used only for screening [F11]. One more thing to read alongside: the clinical guideline above explicitly limits the population for its recommendations to chronic (lasting 3 months or more) TMD-associated pain, and does not apply to acute pain [F16].
下巴脱位可以自己推回去吗？
**本文不提供任何自行复位的方法。** 文献记载的复位是由临床人员执行的处置：在一份 11 例的病例回顾中，有病例在全身麻醉下才施行该手法 [F25]；作者的结论是保守的复位手法在多数病例有效，但这是医疗处置而非居家操作 [F26]。系统综述的结论也是「先充分用尽保守做法、再考虑侵入性手术」，其对象同样是临床处置的选择 [F24]。无法闭口请就诊。
顎が外れたとき、自分で押し戻してもよいですか — **本記事は自分で整復する方法を一切提供しません。** 文献に記載された整復は臨床家が行う処置です。11 例の症例レビューでは、全身麻酔下ではじめて同法を実施した症例があります [F25]。著者の結論は、保存的な整復手技は多くの症例で有効というものですが、これは医学的処置であって家庭での操作ではありません [F26]。システマティックレビューの結論も「まず保存的な方法を十分に使い尽くしてから、侵襲的な手術を検討する」というものであり、その対象も同じく臨床での処置の選択です [F24]。口が閉じられないときは受診してください。
Can I push a dislocated jaw back myself? — **This article provides no method of self-reduction.** The reductions recorded in the literature are procedures performed by clinicians: in a review of 11 cases, one case had the manoeuvre performed only under general anaesthesia [F25]; the authors conclude that the conservative reduction manoeuvre was effective in most cases, but this is a medical procedure and not a home operation [F26]. The systematic review's conclusion is likewise that conservative approaches should be exhausted before invasive surgery is considered, and it too concerns choices among clinical procedures [F24]. If you cannot close your mouth, seek care.
咬合板到底该不该做？
**这题有两个看起来冲突、其实在回答不同问题的证据。** 一方面，以 GRADE 制作的临床指南在与安慰剂或假处置比较的基准下，把可逆式咬合板列为条件性不支持，并把不可逆式口内咬合装置列为强建议不做 [F14][F15]。另一方面，一篇比较咬合板与肉毒毒素注射的荟萃分析显示，两者在开口度上整体没有统计学显著差异，在慢性疼痛分级量表上也没有 [F20][F21]。**两者比较基准不同，不能互相推翻** [F46]。可逆与不可逆的差别，是这一题实务上务必问清楚的一件事 [F14][F15]。
咬合スプリントは結局やるべきですか、やらないべきですか — **この問いには、一見矛盾して見えて実は別の問いに答えている二つのエビデンスがあります。** 一方で、GRADE で作成された臨床ガイドラインは、プラセボまたは偽処置と比較するという基準のもとで、可逆的な咬合スプリントを条件付きで推奨しないとし、不可逆的な口腔内咬合装置を強く推奨しないとしています [F14][F15]。他方で、咬合スプリントとボツリヌス毒素注射を比較したメタアナリシスは、両者の間で開口量に全体として統計学的有意差がなく、慢性疼痛グレーディング尺度でも差がないことを示しています [F20][F21]。**両者は比較の基準が異なり、互いを覆すことはできません** [F46]。可逆的か不可逆的かの違いは、この問いで実務上必ず確認しておくべき点です [F14][F15]。
Should I have an occlusal splint or not? — **There are two pieces of evidence here that look contradictory but are in fact answering different questions.** On one hand, the clinical guideline produced with GRADE, on a benchmark of comparison against placebo or sham, lists reversible occlusal splints as conditionally recommended against, and irreversible intraoral occlusal appliances as strongly recommended against [F14][F15]. On the other hand, a meta-analysis comparing occlusal splints with botulinum toxin injection showed no overall statistically significant difference between the two in mouth-opening range, and none on the graded chronic pain scale either [F20][F21]. **The two use different comparators, and neither overturns the other** [F46]. The difference between reversible and irreversible is the one thing to make sure you clarify in practice on this question [F14][F15].

来源锚定

引用本文

km 編輯部・《颞下颌关节与颌面全指南：TMD 分类地图、保守优先的处置阶梯、急性脱位路径，以及正颌与颌面手术的科别界线｜證據鏈》・IDAEO 知識庫・2026-08-13・https://km.idaeo.ai/reports/dental-pillar-tmj-maxillofacial-evidence

相关文章

更新 2026-08-13T14:17:35.412Z · server-rendered · four-language · IDAEO 知識庫